D.A. Davidson & CO. Raises Stake in Danaher Corporation $DHR

Key Points

• D.A. Davidson & CO. increased its stake in Danaher Corporation by 20.7% during the second quarter, holding a total of 16,780 shares valued at approximately $3.3 million.
• Danaher reported earnings of $1.89 per share, exceeding analyst expectations of $1.72, and experienced a revenue increase of 4.4% year-over-year, totaling $6.05 billion for the quarter.
• The company announced a quarterly dividend of $0.32 per share, resulting in an annualized dividend yield of 0.6%, with the payment date set for October 31st.

D.A. Davidson & CO. raised its position in Danaher Corporation (NYSE:DHR - Free Report) by 20.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,780 shares of the conglomerate's stock after acquiring an additional 2,873 shares during the quarter. D.A. Davidson & CO.'s holdings in Danaher were worth $3,315,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. MGO One Seven LLC raised its holdings in Danaher by 485.7% during the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate's stock worth $5,145,000 after purchasing an additional 20,813 shares in the last quarter. Chicago Capital LLC raised its holdings in Danaher by 11.6% during the second quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate's stock worth $2,634,000 after purchasing an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd raised its holdings in Danaher by 1.6% during the first quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate's stock worth $34,954,000 after purchasing an additional 2,667 shares in the last quarter. Asahi Life Asset Management CO. LTD. acquired a new stake in Danaher during the first quarter worth approximately $539,000. Finally, Horizon Financial Services LLC increased its holdings in shares of Danaher by 20,400.0% in the 1st quarter. Horizon Financial Services LLC now owns 8,200 shares of the conglomerate's stock valued at $1,681,000 after acquiring an additional 8,160 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Robert W. Baird set a $247.00 target price on shares of Danaher in a report on Wednesday. Rothschild & Co Redburn reaffirmed a "neutral" rating and issued a $220.00 target price (down from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Wells Fargo & Company reaffirmed a "positive" rating on shares of Danaher in a report on Thursday. JPMorgan Chase & Co. lifted their target price on shares of Danaher from $260.00 to $270.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Wall Street Zen lowered shares of Danaher from a "buy" rating to a "hold" rating in a research report on Saturday. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and an average target price of $243.39.

Danaher Price Performance

Danaher stock opened at $223.03 on Friday. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The company has a quick ratio of 1.22, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. The firm's 50-day simple moving average is $202.73 and its 200 day simple moving average is $198.36. The firm has a market capitalization of $157.54 billion, a PE ratio of 45.99, a P/E/G ratio of 3.41 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The business had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the firm earned $1.71 EPS. The business's revenue for the quarter was up 4.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities research analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is 26.39%.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.